Shire logo

SHP - Shire Share Price

4690p 0.0  0.0%

Last Trade - 04/01/19

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £12.07bn
Position in Universe th / 1840
Bullish
Bearish
Unlock SHP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SHP Revenue Unlock SHP Revenue

Net Income

SHP Net Income Unlock SHP Revenue

Normalised EPS

SHP Normalised EPS Unlock SHP Revenue

PE Ratio Range

SHP PE Ratio Range Unlock SHP Revenue

Dividend Yield Range

SHP Dividend Yield Range Unlock SHP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SHP EPS Forecasts Unlock SHP Revenue
Profile Summary

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience Ophthalmology, Hematology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Directors
Last Annual December 31st, 2017
Last Interim September 30th, 2018
Incorporated January 28, 2008
Public Since May 23, 2008
No. of Shareholders: 5,265
No. of Employees: 23,044
Sector Healthcare
Industry Biotechnology & Medical Research
Index FTSE4GD UK 50, FTSE Global 100, , ,
Exchange London Stock Exchange (Dual Listing)
Shares in Issue 918,120,398
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SHP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Similar to SHP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.